C71.1 Malignant neoplasm of frontal lobe.
Diagnosis (incl metastases/stage) and year In June 2019 the patient was diagnosed with high-grade G2 diffuse astrocytoma of the occipital lobe, IDH1 mutation detected.
In April 2020 the patient was diagnosed with progression of diffuse astrocytoma to high-grade G3 anaplastic astrocytoma, IDH1 and ATRX mutations detected, MGMT(+).
Surgeries, radiation therapy, chemotherapy (Temozolomide).
The median survival for patients with grade 3 tumors is ∼3 years.
Autologous DCV and CIK (4 doses), cord blood derived NK cells (4 doses) with Interleukin-2, PTAC vaccines over a period of 14 months. Immunotherapy was commenced in December 2020.
Stable disease, with no needed treatment. The patient enjoys life and has only follow-up MRI scans.